We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Value of Stem Cell Related Markers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01265225
Recruitment Status : Withdrawn (no finance)
First Posted : December 23, 2010
Last Update Posted : December 24, 2013
Sponsor:
Information provided by:

Study Description
Brief Summary:
The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.

Condition or disease
Breast Cancer

Study Design

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case-Only
Official Title: Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II
Study Start Date : February 2011
Estimated Primary Completion Date : February 2013
Estimated Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
100 tumor specimens from women with grade 0-11 ductal breast cancer
Criteria

Inclusion Criteria:

  • Ductal Carcinoma in Situ
  • DCIS + Microinvasion stages 1 or 11 without positive lymph nodes

Exclusion Criteria:

  • tumor specimen with higher than grade II
  • BRACA 1 or BRACA 2 mutation
  • Neoadjuvant chemotherapy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01265225


Locations
Israel
Baruch PMC
Poriya, Lower galilee, Israel, 15208
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
More Information

Responsible Party: Dr. I. Schnirer, Baruch Padeh Poriya Medical Center
ClinicalTrials.gov Identifier: NCT01265225     History of Changes
Other Study ID Numbers: 10.CTIL
First Posted: December 23, 2010    Key Record Dates
Last Update Posted: December 24, 2013
Last Verified: December 2013

Keywords provided by The Baruch Padeh Medical Center, Poriya:
breast cancer stages 0-II

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases